Naperiglipron
LY3549492 · Eli Lilly
An oral small-molecule GLP-1 receptor agonist listed in Lilly’s obesity pipeline.
Results availability
No numerical study results are currently summarized for this profile. The development stage and linked studies are listed below.
Mechanism at a glance
Obesity stage by formulation
Latest: The original obesity Phase 2 study was completed in May 2026. A separate obesity/type 2 diabetes Phase 2 protocol was terminated for strategic business reasons after one participant enrolled; Lilly continues to list naperiglipron in its pipeline.
Next: Further sponsor clarification of obesity development; no numerical outcome is inferred from the terminated study.
Clinical study records
Obesity and weight-management studies appear first. Related-condition trials follow by phase, with focus labels to show what each study evaluates. Study stage and results reporting are listed separately. Results summarized above are identified as peer-reviewed or sponsor reported. Otherwise, the label states whether results were posted to a registry or reported in the linked source.
Obesity and weight-management studies
Phase 2 studies2 records
Naperiglipron · obesity with type 2 diabetes
Weight management with type 2 diabetesSeparate Phase 2 study terminated for strategic business reasons after one participant enrolled. This trial-specific decision does not establish discontinuation of the whole candidate.
NCT06683508 · weight management
Weight managementAdults with obesity or overweight; registry study completed May 2026. Further candidate-development status is unclear.
